- "This multibillion-dollar resolution demonstrates the Justice Department’s firm commitment to preventing and combating all forms of health care fraud," Attorney General Eric Holder says, regarding the $2.2B+ Johnson & Johnson (JNJ -0.8%) and its subsidiaries will pay to settle criminal and civil liability related to allegations of off-label marketing and physician kickbacks for Risperdal, Invega, and Natrecor.
- Mentioned and outlined in the DOJ's PR: Janssen's alleged misbranding of Risperdal, the alleged "targeting of vulnerable patients with the drugs Risperdal and Invega for off-label uses," alleged "kickbacks to nursing homes," and alleged "off-label promotion" of Natrecor.
- Full release
JNJ settlement includes $485M in criminal fines and $1.72B in civil settlements
Nov 4 2013, 11:31 ET